Adalimumab for Crohns disease in clinical practice at Mayo clinic: The first 118 patients

Inflammatory Bowel Diseases

Volumn 16, Issue 11, 2010, Pages 1912-1921

  Swoger, Jason M ^a   Loftus Jr , Edward V ^a   Tremaine, William J ^a   Faubion, William A ^a   Pardi, Darrell S ^a   Kane, Sunanda V ^a   Hanson, Karen A ^a   Harmsen, W Scott ^a   Zinsmeister, Alan R ^a   Sandborn, William J ^a  

^a MAYO CLINIC   (United States)

Author keywords

adalimumab; anti tumor necrosis factor antibody; biologic therapy; Crohns disease; inflammatory bowel disease

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

ABSCESS; ADULT; AGED; ARTHRALGIA; ARTICLE; BACTEREMIA; BASAL CELL CARCINOMA; CLINICAL PRACTICE; CLOSTRIDIUM DIFFICILE INFECTION; CORTICOSTEROID THERAPY; CROHN DISEASE; CRYPTOSPORIDIOSIS; DELAYED HYPERSENSITIVITY; DEMOGRAPHY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; ESOPHAGITIS; FATIGUE; FEMALE; FOLLOW UP; GASTROENTERITIS; HERPES ZOSTER; HUMAN; INJECTION SITE PAIN; INJECTION SITE RASH; INJECTION SITE REACTION; INJECTION SITE REDNESS; INJECTION SITE SWELLING; INJECTION SITE URTICARIA; INTESTINE FISTULA; INTESTINE PERFORATION; LEG PAIN; LIVER ABSCESS; LOADING DRUG DOSE; LUNG EMBOLISM; LUPUS LIKE SYNDROME; LYMPHOMA; MAJOR CLINICAL STUDY; MALAISE; MALE; MEDICAL RECORD REVIEW; MONONUCLEOSIS; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; PARESTHESIA; PERISTOMAL ABSCESS; PHLEGMON; PRESCRIPTION; PRIORITY JOURNAL; PROBABILITY; PSORIASIS; RHINOPHARYNGITIS; SERUM SICKNESS; SIDE EFFECT; SINUSITIS; SKIN TINGLING; SMALL INTESTINE OBSTRUCTION; SQUAMOUS CELL CARCINOMA; STREPTOCOCCUS PNEUMONIA; SUICIDE ATTEMPT; THORAX PAIN; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VAGINA MYCOSIS; WEIGHT GAIN; ADOLESCENT; CLINICAL TRIAL (TOPIC); DOSE RESPONSE; MIDDLE AGED; REMISSION; RETROSPECTIVE STUDY;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78249239500     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21272     Document Type: Article

References (32)

1. Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohns disease: Markov model analysis of a population-based cohort. Gastroenterology. 1999; 117: 49-57.
2. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohns disease. Inflamm Bowel Dis. 2002; 8: 244-250.
3. Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006; 130: 940-987.
4. Sandborn WJ, Sutherland LR, Pearson D, et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohns disease. Cochrane Database Syst Rev. 2000: CD000545.
5. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohns disease. Crohns Disease cA2 Study Group. N Engl J Med. 1997; 337: 1029-1035.
6. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohns disease. N Engl J Med. 1999; 340: 1398-1405.
7. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohns disease: the ACCENT I randomised trial. Lancet. 2002; 359: 1541-1549.
8. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohns disease. N Engl J Med. 2004; 350: 876-885.
9. Regueiro M, Siemanowski B, Kip KE, et al. Infliximab dose intensification in Crohns disease. Inflamm Bowel Dis. 2007; 13: 1093-1099.
10. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohns disease. N Engl J Med. 2003; 348: 601-608.
11. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohns disease. Clin Gastroenterol Hepatol. 2004; 2: 542-553.
12. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohns disease: the CLASSIC-I trial. Gastroenterology. 2006; 130: 323-333.
13. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohns disease: results of the CLASSIC II trial. Gut. 2007; 56: 1232-1239.
14. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohns disease: the CHARM trial. Gastroenterology. 2007; 132: 52-65.
15. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007; 146: 829-838.
16. Panaccione R, Colombel JF, Sandborn WJ, et al. Adalimumab maintains long-term remission in moderately to severely active Crohns disease through 2 years (abstract). Gastroenterology. 2008; 134 (4 suppl 1): A-134.
17. Panaccione R, Sandborn WJ, D'Haens G, et al. Adalimumab maintains long-term remission in moderately to severely active Crohns disease after infliximab failure: 1-year follow-up of the Gain trial (abstract). Gastroenterology. 2008; 134 (4 suppl 1): A-133.
18. Sandborn WJ, Hanauer S, Loftus EV, et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohns disease. Am J Gastroenterol. 2004; 99: 1984-1989.
19. Hanauer SB, Sandborn W, and the Practice Parameters Committee of the American College of Gastroenterology. Management of Crohns disease in adults. Am J Gastroenterol. 2001; 96: 635-643.
20. FDA Center for Drug Evaluation and Research. Guideline for industry -clinical safety data management: definitions and standards for expedited reporting. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) 2007.
21. Trinder MW, Lawrance IC,. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting. J Gastroenterol Hepatol. 2009; 24: 1252-1257.
22. Ho GT, Smith L, Aitken S, et al. The use of adalimumab in the management of refractory Crohns disease. Aliment Pharmacol Ther. 2008; 27: 308-315.
23. Ho GT, Mowat A, Potts L, et al. Efficacy and complications of adalimumab treatment for medically-refractory Crohns disease: analysis of nationwide experience in Scotland (2004-2008). Aliment Pharmacol Ther. 2009; 29: 527-534.
24. Mardini HE, Bryson B, Flomenhoft DR, et al. Post marketing clinical experience with adalimumab in Crohns disease (abstract). Gastroenterology. 2008; 134 (4 suppl 1): A-473.
25. Swaminath AC, Rosen MH, Mayer L, et al. Early experience with adalimumab for the treatment of IBD in an academic medical center (abstract). Gastroenterology. 2008; 134 (4 suppl 1): A-664.
26. Karmiris K, Noman M, Schnitzler F, et al. Long-term efficacy and safety of adalimumab treatment in a single-center cohort of Crohns disease patients who failed to infliximab treatment (abstract). Gastroenterology. 2008; 134 (4 suppl 1): A-658.
27. Sandborn WJ, Colombel JF, Rutgeerts P, et al. Benefits of dosage adjustment with adalimumab in Crohns disease: an analysis of the CHARM trial (abstract). Gastroenterology. 2008; 134 (4 suppl 1): A-347-348.
28. Panaccione R, Sandborn W, Colombel J-F, et al. Response after 12 weeks of adalimumab therapy in patients with Crohns disease who were nonresponders at week 4 (abstract). Am J Gastroenterol. 2008; 103 (suppl 1): S379
29. Hanauer SB, Kamm MA, Panaccione R, et al. Steroid-free remission over 2 years in Crohns patients receiving adalimumab: the open-label extension of the CHARM trial (abstract). Gastroenterology. 2008; 134 (4 suppl 1): A-490.
30. Lichtiger S, Binion D, Wolf D, et al. Adalimumab safety in patients with Crohns disease and previous exposure to infliximab: CHOICE trial (abstract). Gastroenterology. 2008; 134 (4 suppl 1): A-489.
31. Colombel JF, Sandborn WJ, Panaccione R, et al. Adalimumab safety in global clinical trials of Crohns disease. Inflamm Bowel Dis. 2009; 15: 1308-1319.
32. Ricart E, Panaccione R, Loftus EV, et al. Infliximab for Crohns disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol. 2001; 96: 722-729.